scholarly journals Nomogram Model for Prediction of Portal Vein Thrombosis in Patients with Liver Cirrhosis After Splenectomy: A Retrospective Analysis of 2 Independent Cohorts

2021 ◽  
Vol 27 ◽  
Author(s):  
Hai-Liang Yuan ◽  
Min Wang ◽  
Wei-Wei Chu ◽  
Fang-Xian Li ◽  
Jing-Jing Lu ◽  
...  
2010 ◽  
Vol 17 (4) ◽  
pp. 367-370 ◽  
Author(s):  
Lucio Amitrano ◽  
Paul R. J. Ames ◽  
Maria Anna Guardascione ◽  
Luis R. Lopez ◽  
Antonella Menchise ◽  
...  

2018 ◽  
Vol 41 (10) ◽  
pp. 611-617
Author(s):  
Tomas Artaza ◽  
Miriam Lopes ◽  
Marta Romero ◽  
Ana-Zaida Gómez ◽  
Gema de la Cruz ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Satoshi Nakayama ◽  
Naoya Murashima

Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT.


Sign in / Sign up

Export Citation Format

Share Document